SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank50
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Percentile
P50
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-14.08%
2024-12.70%
2023-31.67%
2022-115.92%
2021-165.15%
2020337.00%
20190.00%